News
Sleep checks could unlock better menopause care, poll suggests
Women aged 50 to 80 with menopause symptoms were more likely to report sleep problems than those without in a US national poll.
In a cross-sectional analysis of 1,202 US women, investigators found that 56.4 per cent reported sleep problems overall.
Among women with menopause-related symptoms, 75 per cent reported sleep problems, compared with 49.8 per cent of those without such symptoms.
The findings add to existing evidence that sleep disturbances are common during the menopause transition and may be closely tied to active symptom burden.
The Menopause Society has noted that women with vasomotor symptoms during the menopause transition are more likely to report disrupted sleep, and its 2022 hormone therapy position statement says hormone therapy improves sleep in women with bothersome night sweats and hot flushes that disrupt sleep.
Sleep problems in midlife and older women are clinically important because they may affect quality of life, daytime function, cardiometabolic health and long-term wellbeing.
Reviews of sleep disorders during menopause have identified several possible contributors, including vasomotor symptoms, ovarian hormone changes, restless legs syndrome, periodic limb movement disorder and obstructive sleep apnoea.
The findings underscore the importance of asking about sleep when evaluating menopause symptoms and, conversely, considering menopause-related symptom burden when women in midlife and older adulthood present with insomnia, fragmented sleep or poor sleep quality.
“Integrating screening and evidence-based interventions for sleep disturbances into menopause management may improve overall health, quality of life, and long-term outcomes,” Joseph R. White, MD, MS, and colleagues wrote in the study abstract.
White and colleagues analysed survey data from Wave 10 of the National Poll on Healthy Aging, a nationally representative household survey of US adults aged 50 years and older conducted from 21 January to 7 February 2022 to assess timely issues related to health, health care and health policy.
Respondents in the current analysis were stratified and weighted to reflect the US Census. Investigators used chi-square testing to evaluate associations between sleep problems and menopause symptoms.
Among the 1,202 respondents, 65 women were premenopausal with no symptoms, accounting for 7.3 per cent of the weighted sample.
Thirty-seven women were perimenopausal with some symptoms, accounting for 3 per cent, 40 were menopausal within the past year with regular symptoms, accounting for 3.3 per cent, and 35 were menopausal within the past year without regular symptoms, also accounting for 3.3 per cent.
Most respondents were postmenopausal.
A total of 243 women were postmenopausal with symptoms, accounting for 20.8 per cent of the weighted sample, and 765 were postmenopausal without symptoms, accounting for 61.2 per cent.
Overall, 677 respondents reported sleep problems. Women with any menopause-related symptoms were significantly more likely to report sleep problems than women without menopause-related symptoms.
The current findings suggest that sleep assessment may be an important component of that individualised approach.
In primary care, screening may include questions about sleep duration, sleep latency, nighttime awakenings, early-morning awakening, daytime impairment, snoring or witnessed apnoeas, restless legs symptoms, mood symptoms, medication use, alcohol use, and the timing and severity of hot flushes or night sweats.
Investigators did not identify which specific menopause symptoms were most strongly associated with sleep problems.
However, earlier research has shown that greater vasomotor symptom severity is associated with more sleep disturbance, greater sleep-related impairment, worse sleep quality, and greater impairment in daytime activities and work productivity.
Limitations of the analysis include the fact that it was cross-sectional, that sleep problems and menopause symptoms were self-reported, and that it does not specify whether respondents had diagnosed sleep disorders or whether other contributors, such as depression, anxiety, chronic pain, cardiometabolic disease, or medication use, were assessed.
Still, the large, nationally representative sample provides clinically relevant insight into the overlap between menopause-related symptoms and sleep complaints among US women aged 50 to 80 years.
The authors said the findings support routine sleep screening as part of menopause evaluation and follow-up, particularly among women reporting active symptoms.
Pregnant women’s expectations about postpartum sleep may predict sleep quality after birth, outweighing prior sleep and psychiatric history, a study suggests.
The findings suggest attitudes and beliefs about sleep during pregnancy could be a modifiable risk factor for postpartum sleep concerns.
They also indicate that, among women expecting the poorest sleep, higher postpartum anxiety may further worsen sleep quality.
Sammy Dhaliwal, lead author is clinical health psychologist and research fellow in the department of obstetrics and gynaecology at the Perelman School of Medicine at the University of Pennsylvania.
Dhaliwal said: “Most pregnant women in our sample anticipated poor postpartum sleep before it occurred, and it was striking that those expectations predicted worse sleep outcomes even after accounting for factors such as prior sleep disorders, psychiatric history, and number of previous births.
“This suggests that attitudes and beliefs about sleep during pregnancy may represent a modifiable target for early intervention before postpartum sleep problems emerge.”
Sleep disturbance affects an estimated 60 to 80 per cent of postpartum women and is linked to a higher risk of depression and anxiety.
Researchers said it is often regarded as an expected part of life after childbirth rather than a health issue that may be addressed earlier.
The study enrolled 432 pregnant women at about 24 weeks of gestation, meaning around 24 weeks into pregnancy.
Participants completed measures of their expectations about postpartum sleep, current sleep quality using the Pittsburgh Sleep Quality Index, and mood using validated depression and anxiety scales.
Assessments were repeated at six, 12 and 24 weeks postpartum.
A subset of 49 women also wore wrist actigraphy devices at six to eight weeks postpartum.
Actigraphy uses a wearable device, similar to a watch, to estimate sleep and wake patterns based on movement.
The results showed that 70 per cent of pregnant women, or 301 of 432 participants, expected poor sleep in the postpartum period.
Researchers found that predicted sleep disruption during pregnancy was a significant predictor of postpartum sleep concerns.
Among first-time pregnant women without prior health concerns, those who expected greater sleep disturbance had significantly more disrupted sleep after birth, measured by both actigraphy and self-report.
Among women who expected the worst sleep quality, higher postpartum anxiety significantly worsened both measured sleep and self-reported sleep, independent of anxiety levels during pregnancy.
Dhaliwal said the findings point to two possible areas for intervention: addressing sleep-related beliefs during pregnancy and treating postpartum anxiety.
Dhaliwal said: “Postpartum sleep disruption is often treated only after problems develop, but our findings suggest there may be an opportunity to intervene earlier during pregnancy.
“Addressing sleep-related beliefs and postpartum anxiety during prenatal and postpartum care may help improve sleep and emotional well-being in new mothers.”
A weight loss jab may improve fertility outcomes in women with PMOS, early findings from an ongoing clinical trial suggest.
The proof-of-concept analysis found that injectable semaglutide may offer reproductive benefits while also addressing obesity and metabolic dysfunction.
It is the first report to examine how injectable semaglutide may improve reproductive outcomes in women with PMOS while also addressing obesity and metabolic dysfunction.
The work forms part of the ongoing RESTORE clinical trial.
Melanie Cree, professor at CU Anschutz and first author of the report, said: “Women with PMOS frequently face a frustrating choice between treatments that target reproductive symptoms and those that address metabolic health.
“Our early findings suggest injectable semaglutide may have the potential to improve both, offering a more comprehensive approach to care.
“This medication is incredibly promising when someone responds with 10 per cent weight loss.”
The trial is examining whether semaglutide can restore ovulation and improve reproductive health in adolescents and adults with polyendocrine metabolic ovarian syndrome, known as PMOS.
PMOS, formerly known as polycystic ovary syndrome or PCOS, is a hormone and metabolic condition linked to irregular periods, raised testosterone levels, infertility risk, obesity and increased cardiometabolic disease.
Cardiometabolic disease refers to conditions linked to the heart and metabolism, such as heart disease, high blood pressure and type 2 diabetes.
Existing treatments, including metformin and hormonal contraceptives, often do not fully address reproductive and metabolic complications at the same time.
The analysis focused on participants aged 12 to 35 who lost at least 10 per cent of their body weight during treatment.
Researchers said reproductive improvements appeared earlier than expected, prompting them to report preliminary findings while the wider study continues.
Cree is also a paediatric endocrinologist at Children’s Hospital Colorado.
Endocrinologists are doctors who specialise in hormones and hormone-related conditions.
Cree said: “What makes this work particularly important is that it focuses specifically on women with PMOS receiving injectable semaglutide.
“Although GLP-1 medications have transformed obesity treatment, there remains a significant need for rigorous data examining how these therapies affect fertility and reproductive function in this population.”
The RESTORE study is evaluating semaglutide treatment in girls and women with PMOS and obesity.
Its broader aim is to determine whether weight loss and metabolic improvements can restore ovulation and improve reproductive outcomes.
Ovulation is the release of an egg from the ovary, a key part of the menstrual cycle and fertility.
The authors said the findings are from an early proof-of-concept analysis and that larger, longer-term studies will be needed to confirm whether the reproductive benefits last.
The findings suggest injectable semaglutide may become a treatment option for women with PMOS seeking improvements in both metabolic and reproductive health, if future studies confirm the results.
Entrepreneur
Women’s Health Week Europe 2026 opens pitch applications for mainstage showcase at The Emirates Stadium
Women’s Health Week Europe 2026 has opened applications for its flagship start-up Pitches, giving women’s health innovators the chance to present on the mainstage at The Emirates Stadium in London on 7-8 October.
16 finalists will be selected across two categories: Medical Devices & Therapeutics and Consumer & Tech, with the shortlisted companies receiving the opportunity to pitch in front of 700+ investors, corporates, other innovators and strategic partners actively seeking solutions that can scale.
Two categories, one stage
The Medical Devices & Therapeutics category is open to companies working across medical devices, therapeutics and pharma innovation, regulated digital health, and deep-tech or science-led platforms.
The Consumer & Tech category covers consumer health and wellness brands, digital health platforms, wearables and connected data, employer and payor-led solutions, and commerce and marketplace businesses.
Any company treating a condition that affects women exclusively, differently, or disproportionately is eligible to apply.
Applications are completely free, so what do you have to lose?
Apply to pitch at WHW Europe 2026 now.
What’s in it for you?
Unmatched exposure
Present in front of 700+ investors, corporates, clinicians, and strategic partners actively seeking solutions that can scale.
With WHW Europe 2026 relocating to The Emirates Stadium and expanding to 700+ attendees across two stages, the 2026 edition represents the largest platform the series has offered to date.
A proven platform
The WHW Pitch Sessions have become one of the most commercially significant showcases in women’s health, with previous cohorts including companies that have gone on to raise investment and secure major strategic partnerships. 2024 alumni BoobyBiome, closed a £2.5M seed round in the year following their pitch at WHW Europe.
The Watchlist
All registered applicants will have the opportunity to be featured in The Watchlist, WHW Europe’s official directory of women’s health innovators to know, giving companies visibility beyond the pitch stage itself.
Applications close 28 August 2026.
Find out more about WHW Europe.
Menopause2 weeks agoPerimenopause misinformation ‘putting women at risk’
Hormonal health3 weeks agoNHS urged to update website following renaming of PCOS
News2 weeks agoWomen still being failed when they reach menopause, experts say
Insight4 weeks agoPCOS renamed after decade-long campaign to end ‘cyst’ misconception
Events2 weeks agoWomen’s Health Innovation Summit opens submissions for 2026 Innovation Showcase
Insight1 week agoBritish women among angriest in Europe, health survey reveals
Fertility4 weeks agoAI could transform ovarian care through personalisation, study finds
News2 weeks agoThree menopause innovators shortlisted for Femtech World Award